false
0001642380
0001642380
2026-11-16
2026-11-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 16, 2026
Insight
Molecular Diagnostics Inc.
(Exact
name of Registrant as specified in its charter)
| California |
|
1-37648 |
|
27-1041563 |
(State
or other jurisdiction
of incorporation) |
|
(Commission
File No.) |
|
(IRS
Employer
Identification No.) |
2
International Plaza Dr., Suite 510
Nashville,
Tennessee 37217
(Address
of principal executive offices) (Zip code)
(615)
255-8880
Registrant’s
telephone number, including area code
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
Registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
stock, no par value |
|
IMDX |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
1.01 Entry into a Material Definitive Agreement.
On
November 17, 2026, Insight Molecular Diagnostics Inc. (the “Company”) entered into an underwriting agreement
(the “Underwriting Agreement”) with Lake Street Capital Markets, LLC, as underwriter (the “Underwriter”),
relating to an underwritten public offering (the “Offering”) of (i) 8,296,429 shares (the “Shares”)
of the Company’s common stock, no par value per share (“Common Stock”), and (ii) pre-funded warrants
to purchase up to 275,000 shares of Common Stock (the “Pre-Funded Warrants”), at a public offering price of
$1.75 per Share and $1.7499 per Pre-Funded Warrant (which represents the per share offering price for the Shares less the $0.0001 per
share exercise price for each Pre-Funded Warrant). Pursuant to the Underwriting Agreement, the Company also granted the Underwriter a
30-day option to purchase up to an additional 1,285,714 shares of the Common Stock at the public offering price, net of underwriting
discounts and commissions. The Offering is expected to close on or about November 18, 2026 (the “Closing Date”),
subject to the satisfaction or waiver of customary closing conditions.
All
of the securities in the Offering are being sold by the Company.
Aggregate
gross proceeds from the Offering are expected to be approximately $15.0 million, before deducting underwriting discounts and commissions
and estimated expenses payable by the Company. The Company intends to use the net proceeds from the Offering for working capital and
general corporate purposes.
The
Underwriting Agreement additionally contains customary representations, warranties and covenants made by the Company, including an agreement
by the Company that the Company may not dispose of, or announce the offering of, or submit or file any registration statement, prospectus
or prospectus supplement in respect of, any shares or securities convertible into or exchangeable for Common Stock until 90 days following
the date of the Underwriting Agreement, subject to certain exceptions.
The
Underwriting Agreement also provides for customary indemnification by each of the Company and the Underwriters for losses or damages
arising out of or in connection with the Offering, including for liabilities under the Securities Act of 1933, as amended (the “Securities
Act”), other obligations of the parties and termination provisions.
Each
Pre-Funded Warrant has an exercise price of $0.0001 per share of Common Stock, is immediately exercisable upon issuance and may be exercised
at any time until exercised in full. A holder may not exercise any portion of its Pre-Funded Warrants to the extent that the holder,
together with its affiliates and attribution parties, would beneficially own more than 4.99% (or, at the election of the holder, 9.99%)
of the outstanding Common Stock immediately after exercise.
The
Offering is being made pursuant to the Company’s registration statement on Form S-3 (File No. 333-281159) filed with the Securities
and Exchange Commission (the “SEC”) on August 1, 2024, and declared effective on August 7, 2024, a base prospectus
dated August 7, 2024, a preliminary prospectus supplement, dated November 16, 2026 and a prospectus supplement, dated November
17, 2026 and filed with the SEC on November 18, 2026.
The
foregoing descriptions of the material terms of the Underwriting Agreement and Pre-Funded Warrants do not purport to be complete and
are each qualified in their entirety by reference to the Underwriting Agreement and form of Pre-Funded Warrant, respectively, which are
filed as Exhibit 1.1 and Exhibit 4.1, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.
The
legal opinion, including the related consent, of Haynes and Boone, LLP relating to the issuance and sale of the Shares is filed as Exhibit
5.1 hereto.
Item
8.01 Other Events.
On
November 16, 2026, the Company issued a press release announcing the launch of the Offering. On November 17, 2026, the Company issued
a press release announcing the pricing of the Offering. Copies of the press releases are attached hereto as Exhibits 99.1 and 99.2, respectively,
to this Current Report on Form 8-K and incorporated herein by reference.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
| Exhibit
No. |
|
Description |
| 1.1* |
|
Underwriting Agreement, dated November 17, 2026, by and between Insight Molecular Diagnostics Inc. and Lake Street Capital Markets, LLC. |
| 4.1 |
|
Form of Pre-Funded Warrant. |
| 5.1 |
|
Opinion of Haynes and Boone, LLP. |
| 23.1
|
|
Consent of Haynes and Boone, LLP (included in Exhibit 5.1). |
| 99.1
|
|
Press Release, dated November 16, 2026. |
| 99.2 |
|
Press Release, dated November 17, 2026. |
| 104 |
|
Cover
Page Interactive Data File (formatted as Inline XBRL). |
| * |
Certain
schedules, exhibits and similar attachments have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company will provide
a copy of such omitted materials to the Securities and Exchange Commission or its staff upon request. |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
| |
INSIGHT
MOLECULAR DIAGNOSTICS INC. |
| |
|
|
| Date:
November 18, 2026 |
By: |
/s/
Peter Hong |
| |
Name: |
Peter
Hong |
| |
Title: |
Vice
President, General Counsel |
Exhibit 99.1

Insight
Molecular Diagnostics Announces Proposed Public Offering
NASHVILLE,
Tenn. – November 16, 2026 – Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (“iMDx,” “we,”
“us,” “our,” or the “Company”) today announced that it has commenced an underwritten public offering
of shares of its common stock, or, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common
stock. In addition, the Company intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the total number
of shares of common stock offered in the public offering (including shares issuable upon exercise of the pre-funded warrants). The proposed
offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be
completed, or as to the actual size or terms of the offering.
The
Company intends to use the net proceeds from the offering for working capital and general corporate purposes, including but not limited
to research and development in the transplantation category.
Lake
Street Capital Markets is acting as the sole managing underwriter for the offering.
A
shelf registration statement on Form S-3 (File No. 333-281159) relating to these securities has been filed with the Securities and Exchange
Commission (the “SEC”) and has been declared effective. The offering is being made only by means of a prospectus supplement
and accompanying prospectus. Copies of the preliminary prospectus supplement and an accompanying prospectus related to the offering may
also be obtained, when available, by visiting the SEC’s website at http://www.sec.gov or by contacting: Lake Street Capital Markets,
LLC, 121 South 8th Street, Suite 1000, Minneapolis, MN 55402, by telephone at (612) 326-1305 or e-mail at syndicate@lakestreetcm.com.
This
press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any offer,
solicitation or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any such state or jurisdiction.
About
Insight Molecular Diagnostics Inc.
Insight
Molecular Diagnostics is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic
testing to improve patient outcomes.
GraftAssureCore™,
GraftAssureIQ™, GraftAssureDx™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Insight Molecular
Diagnostics Inc.
Forward-Looking
Statements
This
press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended,
Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Words such
as “estimates,” “projects,” “expects,” “anticipates,” “forecasts,” “plans,”
“intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,”
“propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are
intended to identify forward-looking statements. These statements include those pertaining to the consummation of the offering and the
satisfaction of customary closing conditions related to the offering and the use of proceeds therefrom. Forward-looking statements involve
risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of diagnostic tests
or products, the risk that the FDA may not accept our response to its request for additional information, may request further information,
or may not grant marketing authorization for GraftAssureDx on the expected timeline or at all, uncertainty in the results of clinical
trials or regulatory approvals, the capacity of Insight Molecular Diagnostics’ third-party supplied blood sample analytic system
to provide consistent and precise analytic results on a commercial scale, potential interruptions to supply chains, the need and ability
to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, obligations to third parties with
respect to licensed or acquired technology and products, the need to obtain third-party reimbursement for patients’ use of any
diagnostic tests Insight Molecular Diagnostics or its subsidiaries commercialize in applicable jurisdictions, and risks inherent in strategic
transactions such as the potential failure to realize anticipated benefits, legal, regulatory or political changes in the applicable
jurisdictions, accounting and quality controls, potential greater than estimated allocations of resources to develop and commercialize
technologies, or potential failure to maintain any laboratory accreditation or certification. Actual results may differ materially from
the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many
uncertainties that affect the business of Insight Molecular Diagnostics, particularly those mentioned in the “Risk Factors”
section in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and other cautionary statements
found in Insight Molecular Diagnostics’ SEC filings, which are available from the SEC’s website. You are cautioned not to
place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Insight Molecular Diagnostics
undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they
were made, except as required by law.
Investor
Contact:
Alexandra
Grossman
LifeSci
Advisors LLC
imdx@lifesciadvisors.com
Exhibit
99.2

Insight
Molecular Diagnostics Announces Pricing of $15 Million Public Offering
NASHVILLE,
Tenn. – November 17, 2026 – Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (“iMDx,” “we,”
“us,” “our,” or the “Company”) today announced the pricing of its underwritten public offering of
8,296,429 shares of its common stock at a price to the public of $1.75 per share and pre-funded warrants to purchase up to 275,000 shares
of common stock at a price to the public of $1.7499 per pre-funded warrant, which represents the per share public offering price of each
share of common stock, less the $0.0001 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants
in the offering are being sold by iMDx. In addition, the Company has granted the underwriter a 30-day option to purchase up to an additional
1,285,714 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. The gross proceeds
to the Company from the offering are expected to be approximately $15 million, before deducting underwriting discounts and commissions
and other offering expenses. The offering is expected to close on or about November 18, 2026, subject to customary closing conditions.
The
Company intends to use the net proceeds from the offering for working capital and general corporate purposes, including but not limited
to research and development in the transplantation category.
Lake
Street Capital Markets is acting as the sole managing underwriter for the offering.
A
shelf registration statement on Form S-3 (File No. 333-281159) relating to these securities has been filed with the Securities and Exchange
Commission (the “SEC”) and has been declared effective. The offering is being made only by means of a prospectus supplement
and accompanying prospectus. A copy of the final prospectus supplement and an accompany prospectus related to the offering, when available,
can be obtained for free by visiting the SEC’s website at http://www.sec.gov or by contacting: Lake Street Capital Markets, LLC,
121 South 8th Street, Suite 1000, Minneapolis, MN 55402, by telephone at (612) 326-1305 or e-mail at syndicate@lakestreetcm.com.
This
press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any offer,
solicitation or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any such state or jurisdiction.
About
Insight Molecular Diagnostics Inc.
Insight
Molecular Diagnostics is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic
testing to improve patient outcomes.
GraftAssureCore™,
GraftAssureIQ™, GraftAssureDx™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Insight Molecular
Diagnostics Inc.
Forward-Looking
Statements
This
press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended,
Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Words such
as “estimates,” “projects,” “expects,” “anticipates,” “forecasts,” “plans,”
“intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,”
“propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are
intended to identify forward-looking statements. These statements include those pertaining to the consummation of the offering and the
satisfaction of customary closing conditions related to the offering and the use of proceeds therefrom. Forward-looking statements involve
risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of diagnostic tests
or products, the risk that the FDA may not accept our response to its request for additional information, may request further information,
or may not grant marketing authorization for GraftAssureDx on the expected timeline or at all, uncertainty in the results of clinical
trials or regulatory approvals, the capacity of Insight Molecular Diagnostics’ third-party supplied blood sample analytic system
to provide consistent and precise analytic results on a commercial scale, potential interruptions to supply chains, the need and ability
to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, obligations to third parties with
respect to licensed or acquired technology and products, the need to obtain third-party reimbursement for patients’ use of any
diagnostic tests Insight Molecular Diagnostics or its subsidiaries commercialize in applicable jurisdictions, and risks inherent in strategic
transactions such as the potential failure to realize anticipated benefits, legal, regulatory or political changes in the applicable
jurisdictions, accounting and quality controls, potential greater than estimated allocations of resources to develop and commercialize
technologies, or potential failure to maintain any laboratory accreditation or certification. Actual results may differ materially from
the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many
uncertainties that affect the business of Insight Molecular Diagnostics, particularly those mentioned in the “Risk Factors”
section in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and other cautionary statements
found in Insight Molecular Diagnostics’ SEC filings, which are available from the SEC’s website. You are cautioned not to
place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Insight Molecular Diagnostics
undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they
were made, except as required by law.
Investor
Contact:
Alexandra
Grossman
LifeSci Advisors LLC
imdx@lifesciadvisors.com